SCHEMBL954993

SCHEMBL954993

[Zn]CI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL4294074 0.93
SCHEMBL955305 0.72
SCHEMBL185 0.61
SCHEMBL1331208 0.61
Iodide SCHEMBL8245354 0.55
SCHEMBL40928 0.55
SCHEMBL716666 0.55
Hydrogen Sulfide SCHEMBL1241349 0.55
Phosphine SCHEMBL6243734 0.55
SCHEMBL1241351 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192408-A1 A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-10-05 WO disclosed
CN-106102836-B Halogen treatment of heart attack and ischemic injury 弗雷德哈钦森癌症研究中心 2020-02-04 CN disclosed
WO-2017133669-A1 5, 7-DIAZAINDOLE AND 5, 7-DIAZAINDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 WO disclosed
WO-2017133667-A1 PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 WO disclosed
WO-2017133658-A1 4, 7-DIAZAINDOLE AND 4, 7-DIAZAINDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 WO disclosed
WO-2017133665-A1 6,7-DIAZAINDAZOLE AND 6,7-DIAZAINDOLE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 WO disclosed
WO-2017133664-A1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 WO disclosed
CN-103732632-B Method for producing olefin block polymer using Group 4 transition metal complex 住友化学株式会社 2017-07-07 CN disclosed
CN-103732632-A Method for producing olefin block polymer using group 4 transition metal complex SUMITOMO CHEMICAL CO 2014-04-16 CN disclosed
CN-102653570-A Prepolymerization method, prepolymerized catalyst component for addition polymerization, and method for producing addition polymer using the same SUMITOMO CHEMICAL CO 2012-09-05 CN disclosed
US-20110136994-A1 OLEFIN POLYMERIZATION CATALYST AND PRODUCTION PROCESS OF OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-06-09 US disclosed
US-7872080-B2 Processes for producing a catalyst component for addition polymerization, a catalyst and an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-18 US disclosed
US-20110009579-A1 Processes For Producing A Catalyst Component For Addition Polymerization, A Catalyst And An Addition Polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-13 US disclosed
CN-101878233-A Catalyst for polymerization of olefin, and process for production of olefin polymer SUMITOMO CHEMICAL CO 2010-11-03 CN disclosed
US-20090227746-A1 Processes for producing a catalyst component for addition polymerization, a catalyst and an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-09-10 US disclosed
CN-101525395-A Processes for producing a catalyst component for addition polymerization, a catalyst and an addition polymer SUMITOMO CHEMICAL CO 2009-09-09 CN disclosed
CN-1177844-C Cyclopropanes as CGRP antagonists, medicaments contg. said compounds and method for production thereof ���ָ��Ӣ��ķ�������Ϲ�˾ 2004-12-01 CN disclosed
CN-1387526-A Cyclopropanes as CGRP antagonists, medicaments contg. said compounds and method for production thereof BOEHRINGER INGELHEIM PHARMA (DE) 2002-12-25 CN disclosed